Results 121 to 130 of about 1,040,935 (315)

The identification of a TNBC liver metastasis gene signature by sequential CTC‐xenograft modeling

Molecular Oncology, 2019
Triple‐negative breast cancer (TNBC) liver metastasis is associated with poor prognosis and low patient survival. It occurs when tumor cells disseminate from primary tumors, circulate in blood/lymph [circulating tumor cells (CTCs)], and acquire distinct ...
Monika Vishnoi, Nikki Haowen Liu, Wei Yin, Debasish Boral, Antonio Scamardo, David Hong, Dario Marchetti   +6 more
doaj   +1 more source

Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling [PDF]

, 2014
BACKGROUND: Proteomics-based approaches for biomarker discovery are promising strategies used in cancer research. We present state-of-art label-free quantitative proteomics method to assess proteome of renal cell carcinoma (RCC) compared with noncancer ...
J T-J Huang, Bray, S E, Fleming, S., Lamont, D J, D J Lamont, Zakikhani, P, P Zakikhani, M A V Mudaliar, Atrih, A, S Fleming, Zakikhani, P., Lamont, D. J., Barton, G.; id_orcid, G Nabi, G Barton, A Atrih, Bray, S. E., Barton, G, Huang, J. T.-J.; id_orcid, Mudaliar, M. A. V., Atrih, A., Fleming, S, Nabi, G, Nabi, G., Huang, J T-J, S E Bray, Mudaliar, M A V   +26 more
core   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

[18F]-BMS-747158-02PET imaging for evaluating hepatic mitochondrial complex 1dysfunction in a mouse model of non-alcoholic fatty liver disease

EJNMMI Research, 2017
Background Mitochondrial dysfunction is one of the main causes of non-alcohol fatty liver disease (NAFLD). [18F]-BMS-747158-02 (18F-BMS) which was originally developed as a myocardial perfusion imaging agent was reported to bind mitochondrial complex-1 ...
Takemi Rokugawa, Sotaro Momosaki, Miwa Ito, Hitoshi Iimori, Yuki Kato, Kohji Abe   +5 more
doaj   +1 more source

Biomarkers [PDF]

Acta Physiologica, 2016
S, Dietze, A, Patzak
openaire   +2 more sources

Alpha-fetoprotein: from a diagnostic biomarker to a key role in female fertility

, 2007
Alpha-fetoprotein (AFP) is a well-known diagnostic biomarker used in medicine to detect fetal developmental anomalies such as neural tube defects or Down’s syndrome, or to follow up the development of tumors such as hepatocellular carcinomas.
Bakker, Julie, Mees, Christelle De, Szpirer, Josiane, Szpirer, Claude   +3 more
core  

Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines. [PDF]

, 2015
Intracellular cytokine staining combined with flow cytometry is one of a number of assays designed to assess T-cell immune responses. It has the specific advantage of enabling the simultaneous assessment of multiple phenotypic, differentiation and ...
Helen McShane (80704), Hazel M. Dockrell, Caccamo, Nadia, Fletcher, Helen HA, Simone A. Joosten, Helen A. Fletcher, Fletcher, Helen A, Kaatje Smits, Simone A. Joosten (193144), Satti, Iman, Simone A Joosten, Steven G. Smith, Francoise Mascart, Hazel M Dockrell, Satti, I., Francesco Dieli, Fletcher, H., van Meijgaarden, Krista E, Caccamo, N., Ottenhoff, Tom HM, Tom H M Ottenhoff, Ottenhoff, T.H.M., Joosten, S.A., Fletcher, H.A., van Meijgaarden, K., Smith, S., TBVI TB Biomarker Working Group, Ottenhoff, T., Joosten, S., Francesco Dieli (70261), Helen A Fletcher, Krista E. van Meijgaarden (366786), Helen A. Fletcher (80699), McShane, Helen, Iman Satti (795581), Steven G Smith, Mascart, F., Smith, S.G., McShane, H., Smith, Steven G, Steven G. Smith (256794), Nadia Caccamo (297600), Tom H. M. Ottenhoff, Joosten, Simone A, Krista E. van Meijgaarden, Helen McShane, Iman Satti, Meijgaarden, K.E. van, Nadia Caccamo, Tom H. M. Ottenhoff (160303), TBVI TB Biomarker Working Grp, Dockrell, H., van Meijgaarden, Krista KE, Caccamo, N, Hazel M. Dockrell (255469), Smits, Kaatje, Dieli, F, Ottenhoff, Tom H M, Kaatje Smits (795580), Dockrell, H.M., Mascart, Francoise, Francoise Mascart (5665258), Dieli, Francesco, Dockrell, Hazel M, Krista E van Meijgaarden, Smits, K., Dieli, F.   +66 more
core   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

The role of open innovation in biomarker discovery

, 2016
Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable patients for treatment with ...
Gottwald, Matthias, Matthias Gottwald, Khusru Asadullah, Andreas Busch, Landeck, Lilla, Monika Lessl, Asadullah, Khusru, Lilla Landeck, Busch, Andreas, Lessl, Monika   +9 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source